Chief Medical Officer
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead product candidate, CB-839, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. CB-1158 is a first-in- class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body’s cancer-fighting immune cells, known as cytotoxic T -cells. Calithera is headquartered in South San Francisco, California.
Senior Vice President, Clinical Development at Calithera Biosciences
Anymail finder is trusted by tens of thousands of companies to provide accurate contact information to their Sales and Business Development teams.
If you're looking to find the email of Keith Orford at Calithera Biosciences then you've come to the right place.
Wondering if it's keith@calithera.com, keith.orford@calithera.com, orford@calithera.com, or korford@calithera.com? We have the answers for you.